二肽基肽酶4抑制促进2型糖尿病患者远端小管利钠并增加循环SDF-1α1-67
这项前瞻性双盲随机安慰剂对照试验在32例2型糖尿病患者中比较西格列汀与安慰剂。治疗1个月后,西格列汀未改变锂排泄分数,但显著增加总钠排泄分数(1.80±0.01% vs 2.02±1.0%,P=0.012),并增加完整SDF-1α1-67、减少截短型SDF-1α3-67;肾血流动力学、血压、心输出量等未受不良影响。
要点
- 西格列汀治疗1个月显著增加总钠排泄分数,但不改变锂排泄分数。
- 西格列汀增加完整血浆SDF-1α1-67并减少截短型SDF-1α3-67。
- 西格列汀未对肾血流动力学及全身血流动力学产生不良影响。
核心结论
- DPP-4抑制促进远端小管利钠,同时增加完整SDF-1α1-67水平。
- 由于利钠效应位于远端小管,DPP-4抑制不影响管球反馈或损害肾血流动力学功能。
研究设计与样本
- 前瞻性、双盲、随机、安慰剂对照试验,纳入32例2型糖尿病患者。
- 在基线、单次给予西格列汀或安慰剂后每小时、以及1个月时测量肾小管功能与肾及全身血流动力学。
主要发现
- 治疗1个月后,西格列汀组总钠排泄分数从1.32±0.5%升至1.80±0.01%,安慰剂组从2.15±0.6%降至2.02±1.0%,组间比较P=0.012。
- 西格列汀未改变锂排泄分数。
- 西格列汀显著增加完整血浆SDF-1α1-67并减少截短型血浆SDF-1α3-67。
- 西格列汀未对肾血流动力学功能、全身血压、心输出量、每搏输出量和总外周阻力产生不良影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Antihyperglycemic agents, such as empagliflozin, stimulate proximal tubular natriuresis and improve cardiovascular and renal outcomes in patients with type 2 diabetes. Because dipeptidyl peptidase 4 (DPP-4) inhibitors are used in combination with sodium-glucose cotransporter 2 (SGLT2) inhibitors, we examined whether and how sitagliptin modulates fractional sodium excretion and renal and systemic hemodynamic function. RESEARCH DESIGN AND METHODS: We studied 32 patients with type 2 diabetes in a prospective, double-blind, randomized, placebo-controlled trial. Measurements of renal tubular function and renal and systemic hemodynamics were obtained at baseline, then hourly after one dose of sitagliptin or placebo, and repeated at 1 month. Fractional excretion of sodium and lithium and renal hemodynamic function were measured during clamped euglycemia. Systemic hemodynamics were measured using noninvasive cardiac output monitoring, and plasma levels of intact versus cleaved stromal cell-derived factor (SDF)-1α were quantified using immunoaffinity and tandem mass spectrometry. RESULTS: Sitagliptin did not change fractional lithium excretion but significantly increased total fractional sodium excretion (1.32 ± 0.5 to 1.80 ± 0.01% vs. 2.15 ± 0.6 vs. 2.02 ± 1.0%, P = 0.012) compared with placebo after 1 month of treatment. Moreover, sitagliptin robustly increased intact plasma SDF-1α1-67 and decreased truncated plasma SDF-1α3-67. Renal hemodynamic function, systemic blood pressure, cardiac output, stroke volume, and total peripheral resistance were not adversely affected by sitagliptin. CONCLUSIONS: DPP-4 inhibition promotes a distal tubular natriuresis in conjunction with increased levels of intact SDF-1α1-67. Because of the distal location of the natriuretic effect, DPP-4 inhibition does not affect tubuloglomerular feedback or impair renal hemodynamic function, findings relevant to using DPP-4 inhibitors for treating type 2 diabetes.
引用
- Lovshin JA, Rajasekeran H, Lytvyn Y, et al. Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α1-67 in Patients With Type 2 Diabetes. Diabetes Care. 2017. PMID: 28550195. doi:10.2337/dc17-0061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。